Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Anika Therapeutics (ANIK) over the last 11 years, with Q3 2024 value amounting to $248000.0.

  • Anika Therapeutics' Non-cash Items rose 238000.0% to $248000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $248000.0, marking a year-over-year increase of 238000.0%. This contributed to the annual value of $127000.0 for FY2023, which is 8790.48% down from last year.
  • Per Anika Therapeutics' latest filing, its Non-cash Items stood at $248000.0 for Q3 2024, which was up 238000.0% from $300000.0 recorded in Q2 2024.
  • Anika Therapeutics' 5-year Non-cash Items high stood at $4.7 million for Q3 2021, and its period low was $9000.0 during Q1 2022.
  • Over the past 5 years, Anika Therapeutics' median Non-cash Items value was $274000.0 (recorded in 2024), while the average stood at $814857.1.
  • Its Non-cash Items has fluctuated over the past 5 years, first tumbled by 9832.4% in 2022, then skyrocketed by 692222.22% in 2023.
  • Quarter analysis of 5 years shows Anika Therapeutics' Non-cash Items stood at $2.8 million in 2020, then plummeted by 65.18% to $975000.0 in 2021, then rose by 7.69% to $1.0 million in 2022, then tumbled by 87.9% to $127000.0 in 2023, then skyrocketed by 95.28% to $248000.0 in 2024.
  • Its Non-cash Items was $248000.0 in Q3 2024, compared to $300000.0 in Q2 2024 and $316000.0 in Q1 2024.